{"id":"https://openalex.org/W2589893659","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7113","title":"A phase I study of erlotinib in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC)","display_name":"A phase I study of erlotinib in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC)","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2589893659","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7113","mag":"2589893659"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.7113","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7113","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7113","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111457658","display_name":"P. C. Hoffman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. C. Hoffman","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063976463","display_name":"Ann M. Mauer","orcid":"https://orcid.org/0000-0002-3975-0998","observed_orcids":["https://orcid.org/0000-0002-3975-0998"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. M. Mauer","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001508411","display_name":"Daniel C. Haraf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. C. Haraf","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113654286","display_name":"Eric P. Lester","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. P. Lester","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012655110","display_name":"Livia L. Szeto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. L. Szeto","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. E. Vokes","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Oncology Care Assoc, St. Joseph, MI","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"7113","last_page":"7113"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.926800012588501,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.926800012588501,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.07010000199079514,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8690000176429749},{"id":"https://openalex.org/keywords/chemoradiotherapy","display_name":"chemoradiotherapy","score":0.7900000214576721},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9390000104904175},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7549999952316284},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7009999752044678},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.7730000019073486},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.9890000224113464},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.843999981880188},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9950000047683716},{"id":"https://openalex.org/keywords/esophagitis","display_name":"esophagitis","score":0.8190000057220459},{"id":"https://openalex.org/keywords/radiation-toxicity","display_name":"radiation toxicity","score":0.5619999766349792},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5989999771118164},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.6470000147819519},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.4359999895095825},{"id":"https://openalex.org/keywords/thoracic-radiotherapy","display_name":"thoracic radiotherapy","score":0.4659999907016754}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.935111939907074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.649868369102478},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6397278904914856},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5802602767944336},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.5323118567466736},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5264735221862793},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.49455568194389343},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.49022728204727173},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.48177310824394226},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4504028260707855},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.4501035213470459},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.41948214173316956},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4185871481895447},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36805716156959534},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.35261791944503784},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.3497346341609955},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3388620913028717},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2911689877510071},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.11422023177146912},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.7113","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7113","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7113","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1989761818","https://openalex.org/W2363474419","https://openalex.org/W2231949444","https://openalex.org/W2292435599","https://openalex.org/W2911735139","https://openalex.org/W2090154892","https://openalex.org/W2587645327","https://openalex.org/W2970322867","https://openalex.org/W2981828272","https://openalex.org/W2242884525"],"abstract_inverted_index":{"7113":[0],"Background:":[1],"Erlotinib(ER)":[2],"is":[3,261],"an":[4],"inhibitor":[5],"of":[6,18,31,36,46,254],"epidermal":[7],"growth":[8],"factor":[9],"receptor":[10],"tyrosine":[11],"kinase(EGFR-TK)":[12],"approved":[13],"for":[14,55,95,103,115,135],"second":[15],"line":[16],"treatment":[17],"locally":[19],"advanced":[20],"or":[21,292,295],"metastatic":[22],"NSCLC.":[23,56],"Preclinical":[24],"studies":[25],"indicate":[26],"that":[27,48],"small":[28],"molecule":[29],"inhibitors":[30],"EGFR-TK":[32],"enhance":[33],"the":[34,42,141],"effects":[35],"ionizing":[37],"radiation.":[38],"Objective:":[39],"To":[40],"determine":[41],"maximum":[43],"tolerated":[44],"dose":[45,143],"ER":[47,94,134,142,255,271],"can":[49],"be":[50],"administered":[51],"with":[52,60,77,121],"standard":[53,258],"CRT":[54,76,120,192,207,259,273],"Methods:":[57],"Patients":[58],"(pts)":[59],"unresectable":[61],"stage":[62],"III":[63],"NSCLC":[64],"enrolled":[65,154],"in":[66,163,167,171,218,231,277],"this":[67],"2-arm":[68],"phase":[69,279],"I":[70],"dose-escalation":[71],"study.":[72],"Arm":[73,106],"A":[74,186],"included":[75,108],"cisplatin(50mg/m2":[78],"IV":[79,82,101],"d1,8,29,36),":[80],"etoposide(50mg/m2":[81],"d1\u20135,29\u201333),":[83],"chest":[84],"radiation":[85],"therapy(RT)":[86],"(2Gy":[87,128],"QD,":[88,129],"Total":[89,130],"66cGy)":[90,131],"&":[91,112,132,286],"daily":[92,133],"oral":[93],"7":[96,136],"weeks":[97],"followed":[98],"by":[99,283],"docetaxel(75mg/m2":[100],"Q21d)":[102],"3":[104,189,204],"cycles.":[105],"B":[107,201],"induction":[109],"paclitaxel(200mg/m2":[110],"d1)":[111,114],"carboplatin(AUC=6":[113],"two":[116,257],"21-day":[117],"cycles":[118],"then":[119],"weekly":[122,124],"paclitaxel(50mg/m2),":[123],"carboplatin":[125],"(AUC=2),":[126],"RT":[127],"weeks.":[137],"In":[138],"both":[139,219],"arms,":[140,220],"was":[144,216,222],"escalated":[145],"from":[146],"50":[147],"to":[148,256,267],"150mg/day.":[149],"Results:":[150],"Twenty-five":[151],"pts":[152],"were":[153,236],"and":[155,196,211,263],"treated.":[156],"Patient":[157],"characteristics:":[158],"ECOG":[159],"performance":[160],"status":[161],"(0":[162],"17":[164],"pts,":[165,169],"1":[166,172],"6":[168],"2":[170],"pt.),":[173],"median":[174],"age":[175],"62":[176],"(range":[177],"51\u201378),":[178],"gender":[179],"male":[180],"15,":[181],"female":[182],"10.":[183],"For":[184,199],"arm":[185,200],"(n=11),":[187],"grade":[188,203],"toxicities":[190,205],"during":[191,206],"were:":[193,208],"esophagitis(4),":[194,209],"thrombocytopenia(2)":[195],"pulmonary":[197],"infiltrate(1).":[198],"(n=14),":[202],"thrombocytopenia(1)":[210],"bilirubin(1).":[212],"Grade":[213],"3/4":[214],"leukopenia":[215],"noted":[217,230],"but":[221],"not":[223,228,265],"clinically":[224],"significant.":[225],"DLT":[226],"has":[227],"been":[229],"either":[232],"arm.":[233],"Overall":[234],"responses":[235],"(Arm":[237],"A/B):":[238],"Partial":[239],"Response":[240],"(A3/B6),":[241],"Stable":[242],"Disease":[243,246],"(A5/B5),":[244],"Progressive":[245],"(A2/B2),":[247],"Not":[248],"Evaluable":[249],"(A1/B0).":[250],"Conclusions:":[251],"The":[252],"addition":[253],"regimens":[260],"feasible":[262],"does":[264],"appear":[266],"increase":[268],"in-field":[269],"toxicities.":[270],"plus":[272],"warrants":[274],"further":[275],"examination":[276],"a":[278],"II":[280],"trial.":[281],"Supported":[282],"NCI-P30":[284],"CA14599\u201328":[285],"N01":[287],"CM17102\u201302":[288],"Author":[289],"Disclosure":[290],"Employment":[291],"Leadership":[293],"Consultant":[294],"Advisory":[296],"Role":[297],"Stock":[298],"Ownership":[299],"Honoraria":[300],"Research":[301],"Funding":[302],"Expert":[303],"Testimony":[304],"Other":[305],"Remuneration":[306],"Genentech":[307]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-07-14T23:27:15.235271","created_date":"2017-03-03T00:00:00"}